The current model for the development of innovative medical technologies is broken. The costs associated with bringing a new biotechnology product to market now exceed $1B; the time-to-market is about 10 years, which consumes nearly half of the patent life of the underlying technology. Moreover, funding for early stage technology development has nearly disappeared. A new model for the development of innovative medical technologies is required.

We have therefore, formed a international consortium of the drivers of leading translational centers to share knowledge, infrastructure and intellectual property, to practice the principals of open innovation and to jointly execute collaborative projects. RMC's approach intends to accelerate cost-efficient therapy development.